KIAWAH ISLAND, S.C. — In this video from Kiawah Eye & Retina, Jai G. Parekh, MD, MBA, FAAO, discusses improvements in the neurotrophic keratitis treatment landscape.
“Neurotrophic keratitis remains the bane of what we do in ocular surface,” Parekh, of EyeCare Consultants of NJ, said. “For many years, we had no real way to take care of our patients,”
However, with biologics such as Oxervate (cenegermin-bkbj, Dompé) to address the ocular surface, amniotic reconstruction of the ocular surface and pharmacologics in dry eye, “we now are doing a much better job taking care of NK,” he said.